Gilder Gagnon Howe & Co. LLC Trims Position in Boston Scientific Corporation $BSX

Gilder Gagnon Howe & Co. LLC trimmed its position in Boston Scientific Corporation (NYSE:BSX) by 1.7% during the second quarter, HoldingsChannel reports. The institutional investor owned 1,125,253 shares of the medical equipment provider’s stock after selling 18,886 shares during the period. Boston Scientific comprises approximately 1.3% of Gilder Gagnon Howe & Co. LLC’s holdings, making the stock its 19th biggest holding. Gilder Gagnon Howe & Co. LLC’s holdings in Boston Scientific were worth $120,863,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. FWL Investment Management LLC bought a new stake in Boston Scientific during the 2nd quarter worth approximately $26,000. Sound Income Strategies LLC boosted its holdings in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the period. 1248 Management LLC purchased a new position in shares of Boston Scientific during the 1st quarter valued at $26,000. Kilter Group LLC bought a new position in shares of Boston Scientific in the second quarter worth $30,000. Finally, Princeton Global Asset Management LLC purchased a new stake in shares of Boston Scientific in the second quarter worth $32,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Trading Up 0.9%

BSX stock opened at $92.58 on Friday. The company has a market capitalization of $137.24 billion, a PE ratio of 49.51, a price-to-earnings-growth ratio of 1.85 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. Boston Scientific Corporation has a one year low of $85.98 and a one year high of $109.50. The company’s 50 day moving average price is $98.85 and its two-hundred day moving average price is $101.64.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. The company had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the transaction, the executive vice president directly owned 178,342 shares in the company, valued at $17,739,678.74. This trade represents a 21.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director directly owned 24,134 shares in the company, valued at $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 143,095 shares of company stock valued at $14,228,950. 0.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

BSX has been the subject of several recent analyst reports. Royal Bank Of Canada restated an “outperform” rating and set a $125.00 target price on shares of Boston Scientific in a research report on Monday, September 29th. Canaccord Genuity Group reiterated a “buy” rating and set a $132.00 price target on shares of Boston Scientific in a research report on Thursday, October 23rd. Evercore ISI reissued an “outperform” rating on shares of Boston Scientific in a report on Wednesday, October 22nd. Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 11th. Finally, Erste Group Bank lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Boston Scientific has a consensus rating of “Buy” and an average price target of $124.43.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.